Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palivizumab for RSV prevention in high-risk infants
NCT02968173Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2016
- Primary completion
- Jul 2017
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, open-label, single-arm trial of palivizumab in respiratory syncytial virus infection (RSV), sponsored by AbbVie Inc. Primary endpoint: Percentage of Participants With RSV Hospitalization at 6 months. Started Nov 2016; status: completed.
02
Drugs
palivizumab
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02968173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02968173.